GlassScriptPhysician profile
Lorelly Mobley
NPI 1598237349
$8,773.70
in general payments reported to CMS, 2019-2025
42 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,204 · 2022: $1,346 · 2023: $1,610 · 2024: $2,127 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,130 · Education: $94.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,129.55 |
| Education | $94.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,221.60 | 2021-2025 | |
| Janssen Biotech, INC. | $1,022.84 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $658.95 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $600.22 | 2023-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $478.73 | 2021-2023 | |
| Lilly USA, LLC | $355.71 | 2021-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $323.05 | 2024-2025 | Vowst |
| Boston Scientific Corporation | $315.46 | 2021-2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $314.06 | 2021-2025 | Entyvio |
| Genzyme Corporation | $300.16 | 2022-2025 | |
| Celgene Corporation | $290.71 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.64 | 2022-2025 | Xifaxan, Relistor |
| Regeneron Healthcare Solutions, INC. | $202.97 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $181.34 | 2021-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $163.62 | 2024-2025 | Suflave, Sutab |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorelly Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.